Results 151 to 160 of about 42,609 (234)

A renewed perspective on TCA intermediate cis-aconitate: mechanisms and therapeutic options against influenza virus. [PDF]

EMBO Mol Med
Claus C, Kovacevic I.
europepmc   +1 more source

Associations of oseltamivir with neuropsychiatric and behavioral adverse events: A systematic review and meta-analysis. [PDF]

J Manag Care Spec Pharm
Jeong HS, Lee YW, Rhee TG, Shim SR.
europepmc   +1 more source

Fibroblast-derived NEU1 as a therapeutic target for improving cortical bone integrity and fracture healing. [PDF]

Theranostics
Wu Y, Ai H, Zhang C, Qu Y, Tan J, Limjunyawong N, Xu J, Dong S, Luo F, Dou C.   +9 more
europepmc   +1 more source

Influenza With and Without Oseltamivir Treatment and Neuropsychiatric Events Among Children and Adolescents. [PDF]

JAMA Neurol
Antoon JW, Williams DJ, Bruce J, Sekmen M, Zhu Y, Grijalva CG.   +5 more
europepmc   +1 more source

Acquisition of amantadine resistance via M gene reassortment in canine H3N2 influenza virus and elucidation of the resistance mechanism. [PDF]

Virol J
Ga E, Bae E, Xie X, Hwang J, Yeom M, Lim JW, Song D, Na W.   +7 more
europepmc   +1 more source

Modeling Influenza Antiviral Strategies: Reducing Burden and Preventing Resistance. [PDF]

J Infect Dis
Pasco R, Hayden FG, Meyers LA.
europepmc   +1 more source

Oseltamivir‐zanamivir combination therapy suppresses drug‐resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system

European Journal of Pharmaceutical Sciences, 2018
Camilly P Pires de Mello, G. Drusano, Jonathan R. Adams, Matthew Shudt, R. Kulawy, Ashley N Brown   +5 more
semanticscholar   +1 more source

Enhancing the stability of influenza a reporter viruses by recoding the gfp gene. [PDF]

Virol Sin
Hu J, Li J, Li Q, Jiang S, Cao Z, Chen H.   +5 more
europepmc   +1 more source